drugset

drugset / Trial / NCT03346252

The Effect of Botulinum Toxin A on Headache Attributed to TMD

NCT03346252 ↗

Phase 0 Completed 20 enrolled State University of New York at Buffalo

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the effect of of botulinum toxin on the treatment of Headache Attributed to TMD.

Timeline

Start: 2017-05-08
Primary completion: 2021-03-15
Completion: 2021-03-15

Publications

Background Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, List T, Svensson P, Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, De Laat A, de Leeuw R, Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Groupdagger. J Oral Facial Pain Headache. 2014 Winter;28(1):6-27. doi: 10.11607/jop.1151.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Botulinum toxin type A	Protein / enzyme biologic	50 iu	Intramuscular

Indications